CJC-1295 DAC is a research compound. It is not approved by the FDA or any regulatory body for human use. This article is for educational and informational purposes only. Nothing here constitutes medical advice. Consult a qualified physician before considering any peptide use.
CJC-1295 DAC is administered via subcutaneous injection at 1-2 mg per injection once or twice weekly. Subcutaneous injections into the abdominal fat or thigh are most common. Proper reconstitution with bacteriostatic water is required first.
How Do You Inject CJC-1295 DAC?
CJC-1295 DAC is administered via subcutaneous injection. For most researchers, subcutaneous injection is the standard approach — it's simple, relatively painless, and effective for GHRH analog with extended half-life compounds.
This guide covers injection technique, site selection, needle choices, and common mistakes.
How Do You Prepare for a CJC-1295 DAC Injection?
Step 1: Wash your hands thoroughly.
Step 2: Clean the top of the CJC-1295 DAC vial and BAC water vial with alcohol swabs. If not yet reconstituted, see our CJC-1295 DAC reconstitution guide.
Step 3: Draw your dose (1-2 mg per injection) into an insulin syringe. Use our calculator for exact units.
Step 4: Clean the injection site with an alcohol swab and let it dry.
What Is the Correct Injection Technique?
Subcutaneous (most common): Pinch a fold of skin — typically abdominal fat 2+ inches from the navel, or the thigh. Insert the needle at a 45-degree angle. Push the plunger slowly and steadily. Hold for 5 seconds, then withdraw.
Intramuscular (less common for CJC-1295 DAC): Insert the needle at 90 degrees into the muscle (deltoid or vastus lateralis). This route provides faster absorption but isn't necessary for most peptide protocols.
Rotate injection sites to prevent lipodystrophy (fat tissue changes from repeated injections in the same spot).
What Size Needle Should You Use?
For subcutaneous CJC-1295 DAC injections, 29-31 gauge insulin needles (½ inch or 8mm) are standard. These are thin enough to be nearly painless while long enough for proper subcutaneous delivery.
Use a fresh needle for every injection. Never reuse or share needles.
Calculate Your CJC-1295 DAC Dose
Use our free peptide dosing calculator to get exact reconstitution math and syringe units for CJC-1295 DAC.
Open Calculator →What Are Common Injection Side Effects?
Mild redness, swelling, or itching at the injection site is normal and typically resolves within hours. Small bruises can occur, especially if you hit a capillary.
If you experience persistent pain, swelling, warmth, or redness lasting more than 24 hours, discontinue and consult a healthcare provider — these may indicate infection.
Bottom Line on CJC-1295 DAC Injection
CJC-1295 DAC is administered via subcutaneous injection at 1-2 mg per injection once or twice weekly. Subcutaneous injection with a 29-31 gauge insulin needle into abdominal fat is the standard technique. Rotate sites and use a fresh needle every time.
Complete Guide
CJC-1295 DAC : Benefits, Dosage, Side Effects & Research
Related Reading
- CJC-1295 DAC Dosage Guide
- CJC-1295 DAC Benefits
- CJC-1295 DAC Side Effects
- CJC-1295 DAC Stacking Guide
- CJC-1295 DAC Cycle Guide
- CJC-1295 DAC Research
Research-Grade Sourcing
If you're going to research CJC-1295 DAC, source matters. These are the suppliers WolveStack has vetted for purity and third-party testing.
Frequently Asked Questions
What is CJC-1295 DAC?
CJC-1295 DAC (CJC-1295 with Drug Affinity Complex) is a GHRH analog with extended half-life. Synthetic GHRH analog with four amino acid substitutions conjugated to a drug affinity complex that binds endogenous albumin. It is researched for sustained GH elevation, elevated IGF-1 levels, enhanced protein synthesis, improved body composition, increased muscle mass.
What is the recommended CJC-1295 DAC dosage?
Common dosages: 1-2 mg per injection administered once or twice weekly via subcutaneous injection. Cycle length: 12-16 weeks. Half-life: 6-8 days. Use our peptide calculator for exact reconstitution math.
What are the side effects of CJC-1295 DAC?
Water retention, joint aches, fluid retention, mild headache. Sustained GH elevation may cause more pronounced side effects than pulsatile release versions. One subject death in Phase II trial was attributed to unrelated coronary artery disease.
Is CJC-1295 DAC safe?
CJC-1295 DAC has shown a preliminary safety profile in research. Not FDA-approved. Development discontinued post-Phase II. WADA banned. Available as research peptide. All research should follow appropriate safety protocols.